Study of NLG802 with temozolomide for progressive brain cancer in kids
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests an experimental drug called NLG802 combined with the chemotherapy drug temozolomide for children and young adults whose brain or spinal cancer has come back or has not responded to treatment. The goal is to see if this combination can help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 5 and 21 years old.
- Your brain or spinal cancer has returned or is not responding to treatment.
- You are able to swallow pills.
- You have had at least 3 weeks since your last chemotherapy, and at least 4 weeks since last radiation or immunotherapy.
- Your blood counts, kidney, and liver function are within the needed ranges.
- You (or your parent) agree to sign a consent form and provide tumor tissue and blood samples for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether Tumor Treating Fields (a wearable electrical device placed on the scalp) combined with temozolomide can treat brainstem gliomas (tumors in key parts of the brainstem). It may help slow tumor growth and improve outcomes for adults who have already finished surgery/radiation or are otherwise ready for the next treatment step.
This Phase 1 study tests a combination treatment (ibrutinib plus indoximod along with chemotherapy) for children with brain tumors that have come back or are hard to treat. It may help shrink active tumor or control the disease when standard treatments can’t cure it.
This trial tests a new combination of two drugs (tarlatamab and temozolomide) for people with certain types of aggressive brain or central nervous system tumors that have come back or not responded to standard treatment. The hope is that this combination may work better against tumors that have a specific marker called DLL3.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
This trial tests a combination of three drugs (temozolomide, anlotinib, and bemarituzumab) along with radiation therapy for children with a type of brain tumor called diffuse midline glioma. The goal is to see if this approach can help shrink or control the tumor when surgery cannot remove it completely.
Hear when a new Progressive Pediatric Brain Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.